A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
Active, not recruiting
Eli Lilly and Company
Phase 1
2009-12-07
The purpose of this study is to determine a safe dose of LY2835219 to be given to
participants with advanced cancer and to determine any side effects that may be associated
with LY2835219 in this population. Efficacy measures will be used to assess the activity of
LY2835219 in this population.
A Study of LY3023414 in Participants With Advanced Cancer
Active, not recruiting
Eli Lilly and Company
Phase 1
2012-07-31
The purpose of this study is to find a recommended dose level and schedule of dosing
LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The
study will also explore the changes to various markers in blood cells and potentially tumor
cells. Finally, the study will help document any antitumor activity this drug may have.
In Part A of this study, participants with advanced/metastatic cancer (including lymphoma)
will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in
different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.
A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants
Completed
Eli Lilly and Company
Phase 1
2013-08-01
This type of study is called a radiolabeled study. For this study, LY2835219 (study drug) has
been specially prepared to contain radiolabeled carbon [^14C]. [^14C] is a naturally
occurring radioactive form of the element carbon. This study will help understand how the
drug appears in the blood, urine, and stool after it is administered.
In addition, this study will also evaluate the safety and tolerability of a single dose of
LY2835219 when given to healthy participants. Information about any side effects that may
occur will also be collected.
This study will last about 3 weeks for each participant, not including screening.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
